Idarubicin
Idarubicin
Anthracycline antileukemic drug
Idarubicin /ˌaɪdəˈruːbɪsɪn/ or 4-demethoxydaunorubicin is an anthracycline antileukemic drug. It inserts[1] itself into DNA and prevents DNA unwinding by interfering with the enzyme topoisomerase II. It is an analog of daunorubicin, but the absence of a methoxy group increases its fat solubility and cellular uptake.[2] Similar to other anthracyclines, it also induces histone eviction from chromatin.[3]
It belongs to the family of drugs called antitumor antibiotics.
It is currently combined with cytosine arabinoside as a first line treatment of acute myeloid leukemia.[4]
It is used for treatment of acute lymphoblastic leukemia and chronic myelogenous leukemia in blast crisis.[5]
It is distributed under the trade names Zavedos (UK) and Idamycin (USA).